by DealForma Analysts | Dec 9, 2022 | Deal of the Month
November 2022 Top Biopharma Deal: POINT – Lantheus for cancer drugs PNT2002 and PNT2003 November 2022 Top Biopharma Deal Upfront POINT development and commercialization deal with Lantheus for PNT2002 and PNT2003 Announced: November 11, 2022 Total Deal...
by DealForma Analysts | Nov 4, 2022 | Deal of the Month
October 2022 Top Biopharma Deal: MacroGenics – Gilead for blood cancer drug MGD024 October 2022 Top Biopharma Deal Upfront MacroGenics research partnership with Gilead with an option to license MGD024 Announced: October 17, 2022 Total Deal Value: $1,760M Upfront...
by DealForma Analysts | Oct 3, 2022 | Deal of the Month
Deal of the Month September 2022 Top Biopharma Deal: SpringWorks – GSK for Nirogacestat in combination with Blenrep September 2022 Top Biopharma Deal Upfront SpringWorks development and commercialization deal expansion with GSK for Nirogacestat in combination...
by DealForma Analysts | Sep 2, 2022 | Deal of the Month
Deal of the Month August 2022 Top Biopharma Deal: Sanofi – Innovent for Cancer Drugs SAR408701 and SAR444245 August 2022 Top Biopharma Deal Upfront Sanofi development and commercialization deal with Innovent for SAR408701 and SAR444245 Announced: August 24, 2022...
by DealForma Analysts | Aug 22, 2022 | Deal of the Month
Deal of the Month July 2022 Top Biopharma Deal: Orion – MSD for Prostate Cancer Drug ODM-208 July 2022 Top Biopharma Deal Upfront Orion co-development and co-commercialization deal with MSD for ODM-208 Announced: July 13, 2022 Total Deal Value: $290M +...
by DealForma Analysts | Aug 22, 2022 | Deal of the Month
Deal of the Month June 2022 Top Biopharma Deal: Sanofi – Regeneron Pharmaceuticals for Cancer/Inflammation drug Libayo June 2022 Top Biopharma Deal Upfront Sanofi development and commercialization deal with Regeneron for Libtayo (Amended Agreement) Announced:...
by DealForma Analysts | Jun 10, 2022 | Deal of the Month
Deal of the Month May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation May 2022 Top Biopharma Deal Upfront Dragonfly Therapeutics development and commercialization deal with Gilead Sciences for solid...
by DealForma Analysts | May 10, 2022 | Deal of the Month
Deal of the Month April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment April 2022 Top Biopharma Deal Upfront Harbour BioMed development and commercialization deal with AstraZeneca for solid tumors Announced: April...
by DealForma Analysts | Apr 28, 2022 | Deal of the Month
Deal of the Month March 2022 Top Biopharma Deal: IGM Biosciences – Sanofi IgM Antibody Platform for Cancer and Immunology/Inflammation March 2022 Top Biopharma Deal Upfront IGM development and commercialization deal with Sanofi for cancer, immunology, and...
by DealForma Analysts | Mar 10, 2022 | Deal of the Month
Deal of the Month February 2022 Top Biopharma Deal: Heidelberg – Huadong ATAC Candidates for Cancer Treatment February 2022 Top Biopharma Deal Upfront Heidelberg development and commercialization deal with Huadong for HDP-101, HDP-103, and options for two more...
